Published on in Vol 8, No 11 (2022): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/38898, first published .
The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

Journals

  1. Fogolari M, Francesconi M, De Florio L, Giovanetti M, Veralli R, De Flora C, Maruotti A, Scarpa F, Spoto S, Sambuco F, Riva E, Ciccozzi M, Angeletti S. SARS-CoV-2 Variants in COVID-19 Disease: A Focus on Disease Severity and Vaccine Immunity in Patients Admitted to the Emergency Department. Journal of Personalized Medicine 2022;12(12):2001 View
  2. Chi H, Chiu N, Chen C, Weng S, Lien C, Lin C, Hu Y, Lei W, Tai Y, Lin L, Liu L, Lin C. To PCR or not? The impact of shifting policy from PCR to rapid antigen tests to diagnose COVID-19 during the omicron epidemic: a nationwide surveillance study. Frontiers in Public Health 2023;11 View
  3. Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S, Lapa D, Haggiag S, Prosperini L, Cuzzi G, Salmi A, Quartuccio M, Altera A, Garbuglia A, Ascoli Bartoli T, Galgani S, Notari S, Agrati C, Puro V, Nicastri E, Gasperini C, Goletti D. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose. International Journal of Molecular Sciences 2023;24(10):8525 View
  4. Pérez-Tasigchana F, Valcárcel-Pérez I, Arias-Quispe M, Astudillo L, Bruno A, Herrera G. M, Armas R, de Mora D, Pinos J, Olmedo A, Salas R, Jimbo-Sotomayor R, Chiluisa C, Acosta P, Sánchez X, Whittembury A. Effectiveness of COVID-19 vaccines in Ecuador: A test-negative design. Vaccine: X 2023;15:100404 View